Navigation Links
Anti-inflammatory drug can prevent neuron loss in Parkinson's model
Date:7/25/2014

An experimental anti-inflammatory drug can protect vulnerable neurons and reduce motor deficits in a rat model of Parkinson's disease, researchers at Emory University School of Medicine have shown.

The results were published in the Journal of Parkinson's Disease.

The findings demonstrate that the drug, called XPro1595, can reach the brain at sufficient levels and have beneficial effects when administered by subcutaneous injection, like an insulin shot. Previous studies of XPro1595 in animals tested more invasive modes of delivery, such as direct injection into the brain.

"This is an important step forward for anti-inflammatory therapies for Parkinson's disease," says Malu Tansey, PhD, associate professor of physiology at Emory University School of Medicine. "Our results provide a compelling rationale for moving toward a clinical trial in early Parkinson's disease patients."

The new research on subcutaneous administration of XPro1595 was funded by the Michael J. Fox Foundation for Parkinson's Research (MJFF). XPro1595 is licensed by FPRT Bio, and is seeking funding for a clinical trial to test its efficacy in the early stages of Parkinson's disease.

"We are proud to have supported this work and glad to see positive pre-clinical results," said Marco Baptista, PhD, MJFF associate director of research programs. "A therapy that could slow Parkinson's progression would be a game changer for the millions living with this disease, and this study is a step in that direction."

In addition, Tansey and Yoland Smith, PhD, from Yerkes National Primate Research Center, were awarded a grant this week from the Parkinson's Disease Foundation to test XPro1595 in a non-human primate model of Parkinson's.

Evidence has been piling up that inflammation is an important mechanism driving the progression of Parkinson's disease. XPro1595 targets tumor necrosis factor (TNF), a critical inflammatory signaling molecule, and is specific to the soluble form of TNF. This specificity would avoid compromising immunity to infections, a known side effect of existing anti-TNF drugs used to treat disorders such as rheumatoid arthritis.

"Inflammation is probably not the initiating event in Parkinson's disease, but it is important for the neurodegeneration that follows," Tansey says. "That's why we believe that an anti-inflammatory agent, such as one that counteracts soluble TNF, could substantially slow the progression of the disease."

Postdoctoral fellow Christopher Barnum, PhD and colleagues used a model of Parkinson's disease in rats in which the neurotoxin 6-hydroxydopamine (6-OHDA) is injected into only one side of the brain. This reproduces some aspects of Parkinson's disease: neurons that produce dopamine in the injected side of the brain die, leading to impaired movement on the opposite side of the body.

When XPro1595 is given to the animals 3 days after 6-OHDA injection, just 15 percent of the dopamine-producing neurons were lost five weeks later. That compares to controls in which 55 percent of the same neurons were lost. By reducing dopamine neuron loss with XPro1595, the researchers were also able to reduce motor impairment. In fact, the degree of dopamine cell loss was highly correlated both with the degree of motor impairment and immune cell activation.

When XPro1595 is given two weeks after injection, 44 percent of the vulnerable neurons are still lost, suggesting that there is a limited window of opportunity to intervene.

"Recent clinical studies indicates there is a four or five year window between diagnosis of Parkinson's disease and the time when the maximum number of vulnerable neurons are lost," Dr. Tansey says. "If this is true, and if inflammation is playing a key role during this window, then we might be able to slow or halt the progression of Parkinson's with a treatment like XPro1595."


'/>"/>
Contact: Quinn Eastman
qeastma@emory.edu
404-727-7829
Emory Health Sciences
Source:Eurekalert

Related medicine news :

1. Some aggressive cancers may respond to anti-inflammatory drugs
2. African American women more resistant anti-inflammatory effect aspirin than white women
3. Nonsteroidal anti-inflammatory agent slows rate of progression of neurodegenerative disease
4. The Natural Anti-Inflammatory Supplement "Natural Body Defense" Released Online For Purchase with Extra discount Offers
5. Natural Body Defense - All Natural Anti-Inflammatory Support Supplement Now Available in the Market With 1 Extra Bottle Offer!
6. Natural Anti-Inflammatory and Anti-Oxidant Benefits Found in the Pure Daily Body Oil from Sublime Beauty®; Now Available
7. Research shows genetic anti-inflammatory defect predisposes children to lymphoma
8. Birds appear to lack important anti-inflammatory protein
9. Anti-inflammatory and anti-thrombogenic effects of atorvastatin in acute ischemic stroke
10. Revitol Rosacea Now Comes with Anti-Inflammatory Ingredients to Remove Redness and Flushing
11. Revitol Rosacea Now Comes with Anti-Inflammatory Ingredients to Remove Redness and Flushing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... NORTHBROOK, Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the ... joins Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... appointed General Manager of Astellas Farma Colombia ... ...
(Date:6/23/2016)... Research and Markets has announced ... Analysis (United States, China, Japan, Brazil, United Kingdom, Germany, ... offering. Surgical Procedure ... planners, provides surgical procedure volume data in a geographic ... in-depth analysis of growth drivers and inhibitors, including world ...
Breaking Medicine Technology: